Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 112

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 112
---
 flows
used in or provided by (as applicable) operating, investing and financing activities for the periods presented. For a discussion of our
net cash flows for the year ended December 31, 2022, please see “ Item 5. Operating and Financial Review and Prospects - B.
Liquidity and Capital Resources - Cash Flows” in our Annual Report on Form 20-F for the year ended December 31, 2023, which
we filed with the SEC on March 28, 2024:

                                                                      2024                   2023                   2022               
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  ( U. S. dollars, in thousands)                                                                                                       
  Net cash used in operating activities                               $         (19,700      $         (21,577      $         (23,678  
  Net cash provided by (used in) investing activities                             9,622                 (4,538                 13,274  
  Net cash provided by financing activities                                       4,656                 18,152                  9,343  
  Exchange rate differences - cash and cash equivalents balances                    (49                   (245                 (2,284  
  Decrease in cash and cash equivalents                               $          (5,471      $          (8,208      $          (3,345  

Cash Used in Operating Activities

Cash used in operating
activities for the year ended December 31, 2024 was approximately $19.7 million and primarily reflects our overall loss of approximately
$18.1 million, as adjusted upwards to eliminate certain non-cash items that were taken into account in calculating, and that decreased,
our overall loss, including approximately $6.5 million of non-cash financial income related to remeasurement of pre-funded warrants and
warrants, approximately $0.7 million of non-cash net financing income and approximately $3.3 million of changes in asset and liability
items, mainly due to an increase in inventories and trade receivables and a decrease in trade payables, payroll accrual balances, deferred
revenues and other advances, partially offset by a decrease in other receivables and prepaid expenses. These upwards adjustments
to cash used were partially offset by approximately $2.7 million of non-cash expenses related to an excess of initial fair value of pre-funded
warrants over the transaction proceeds, approximately $1.8 million of share-based